To assess the potential impact of MEN1611 on the viability of NSCLC cell lines sensitive and resistant to EGFR-TKIs (i.e., erlotinib and gefitinib), dose–response experiments were conducted on NSCLC cell lines with a wild-type or mutated PIK3CA gene (Figure 1A). This evidence concerns the gene EGFR and non-small cell lung carcinoma.